Bracco subsidiary Blue Earth Therapeutics has expanded its partnership with Seibersdorf Labor to include manufacture of its investigational radiohybrid actinium-225 (Ac-225)-based radioligand therapy.
The agreement will supply the prostate-specific membrane antigen (PSMA)‐targeted therapeutic radiopharmaceutical rhPSMA‐10.1 to EU, U.K., and U.S. clinical trial sites, the company said. rhPSMA‐10.1 can be radiolabeled with imaging isotopes for PET imaging or with therapeutic isotopes such as lutetium-177 (Lu-177) or Ac-225.
Blue Earth Therapeutics' rhPSMA compounds have not yet received regulatory approval.
%20mol%20oct.0h6Wt2LMeF.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
%20mol%20oct.0h6Wt2LMeF.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
